Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 40fludarabine 36fludarabine phosphate 28Tacrolimus 20Whole-Body Irradiation 18Mycophenolic Acid 18Busulfan 18Melphalan 16thymoglobulin 14Rituximab 13Antilymphocyte Serum 12venetoclax 11Thiotepa 10Nivolumab 9Methotrexate 9Granulocyte Colony-Stimulating Factor 9Stem Cell Transplantation 8Peripheral Blood Stem Cell Transplantation 8Cyclosporine 8trametinib 7Sirolimus 7Cytarabine 7Azacitidine 7AP 1903 reagent 7Filgrastim 6Dexamethasone 6aldesleukin 5Mesna 5Ipilimumab 5Interleukin-2 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × lorvotuzumab mertansine × Lymphoid × Clear all
NCT02420873 2018-08-28

An Open-label Phase II Study of Lorvotuzumab Mertansine

M.D. Anderson Cancer Center

Phase 2 Completed
9 enrolled 7 charts
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡